文献速递生殖医学

快速卵母细胞玻璃化与复温方案的临床前验证:效率与标准方法相当

Preclinical validation of fast oocyte vitrification and warming protocols with comparable efficiencies to a standard method.
PubMed 文献 · Hum Reprod · 2025-01-01

本研究在鼠、兔及废弃人卵母细胞中比较快速玻璃化(FV)与快速复温(FW)方案与标准方案,发现FV/FW显著缩短暴露时间,且卵母细胞存活率、纺锤体完整性和发育潜能相当,小鼠活产率无显著差异。

要点

  • FV/FW方案显著缩短玻璃化暴露时间,鼠卵存活率97.2%与标准方案94.2%无显著差异。
  • 小鼠胚胎移植活产率FV/FW 38.7% vs 标准47.8%,无统计学显著不良影响。
  • 废弃人卵母细胞验证FV/FW存活率97.1%(n=103),支持进一步临床研究。

核心结论

  • 在测试的动物模型中,FV和FW方案显著缩短暴露时间,未损害卵母细胞完整性和发育潜能,提供更高效的IVF实验室工作流程。

研究设计与样本

  • 临床前研究,使用小鼠和兔卵母细胞及部分废弃人卵母细胞,随机分配至快速或标准玻璃化/复温方案。
  • 实验阶段包括减数分裂纺锤体完整性评估、复温后存活与发育率评估、小鼠胚胎移植评估足月发育潜能、人卵母细胞计算机模型开发与验证。

主要发现

  • 小鼠卵母细胞FV/FW存活率97.2%(n=249)与SV/SW 94.2%(n=224)无显著差异,但显著高于SV/FW 91.7%(n=229,P=0.008)。
  • ICSI后囊胚率:SV/SW 83.4%,FV/FW 80.9%,SV/FW 75.9%,新鲜对照86.4%(n=123)。
  • 小鼠胚胎移植活产率:FV/FW 38.7% vs SV/SW 47.8% vs SV/FW 43.2%,无统计学显著不良影响。
  • 兔MII卵母细胞存活率各方案90%-100%,囊胚发育率FV/FW 28.6% vs SV/SW 22.2% vs SV/FW 13.6%。
  • 废弃人卵母细胞存活率:SV/FW 94.1%(n=101),FV/FW 97.1%(n=103)。

临床怎么用

  • 作者认为FV和FW方案是有前景的替代方法,可提高实验室工作效率并减少卵母细胞暴露于潜在有害冷冻保护剂。
  • 作者指出需进一步临床试验确认FV方案在常规IVF临床实践中的安全性和有效性。

局限性

  • 本研究为临床前研究,涉及动物模型和废弃人卵母细胞。
  • 需进一步临床试验确认FV方案在常规IVF临床实践中的安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can fast vitrification (FV) and fast warming (FW) protocols effectively reduce oocyte exposure times to cryoprotectants while maintaining survival, developmental potential, and laboratory efficiency compared to a standard protocol? SUMMARY ANSWER: FV and FW protocols significantly reduce exposure times compared to a standard protocol without compromising oocyte integrity or developmental potential in the animal models tested, offering a more efficient workflow for IVF laboratories. WHAT IS KNOWN ALREADY: Vitrification is a widely used oocyte cryopreservation technique in IVF centers, but current protocols are time-consuming and labor-intensive. Additionally, prolonged exposure to cryoprotectants under non-physiological conditions, such as high osmolality and room temperature, raises concerns about oocyte viability and developmental potential. STUDY DESIGN, SIZE, DURATION: This preclinical study involved oocytes from two animal models (mouse and rabbit) and a subset of discarded human oocytes. Experimental stages included: (a) evaluation of meiotic spindle integrity; (b) assessment of survival and developmental rates post-warming and ICSI; (c) embryo transfers in mice to evaluate full-term developmental potential; and (d) development and validation of an in silico model for human oocytes. PARTICIPANTS/MATERIALS, SETTING, METHODS: Mouse and rabbit oocytes were randomly allocated to either a fast or standard vitrification (SV)/standard warming (SW) protocol. Survival and developmental rates were assessed post-warming. Meiotic spindle integrity and chromosomal alignment were analyzed using immunofluorescence. Full-term development was evaluated through embryo transfers in mice. Theoretical osmotic modeling was performed on human oocytes to predict their behavior under FV conditions, with empirical validation using discarded human oocytes. MAIN RESULTS AND THE ROLE OF CHANCE: The FV/FW protocol significantly reduced the time required for vitrification compared to a SV/SW protocol, while maintaining comparable oocyte survival, meiotic spindle integrity, and developmental rates in animal models. In mouse oocytes, the FV/FW protocol achieved the highest survival rate (n = 249 oocytes; 97.2%) not statistically significantly different from the SV/SW protocol (n = 224 oocytes, 94.2%), but significantly higher (P = 0.008) than the SV/FW group (n = 229 oocytes, 91.7%). After ICSI, the SV/SW group reached 83.4% blastocyst rates, followed by the FV/FW group at 80.9%, and the SV/FW group at 75.9%, all comparable to the fresh oocyte control group (n = 123) with 86.4%. Embryo development after ICSI resulted in blastocyst formation rates of 80.9% for the FV/FW protocol compared to 83.4% in the SV/SW and 86.4% in the SV/FW group. Embryo transfer outcomes in mice demonstrated no statistically significant adverse effects on implantation or full-term development, with live birth rates of 38.7% (FV/FW) compared to 47.8% (SV/SW) and 43.2% (SV/FW). Survival rates of rabbit metaphase II oocytes ranged between 90% and 100% across all protocols, while blastocyst developmental rates were higher in the FV/FW group (28.6%) compared to the SV/SW group (22.2%) and the SV/FW group (13.6%). The mathematical in silico osmotic model predicted favorable responses for human oocytes, which were confirmed experimentally in discarded human oocytes with survival rates of 94.1% (n = 101) for the SV/FW protocol and 97.1% (n = 103) for the FV/FW protocol. LARGE SCALE DATA: NA. LIMITATIONS, REASONS FOR CAUTION: This study was preclinical and involved animal models and discarded human oocytes. Further clinical trials are required to confirm the safety and efficacy of FV protocols in routine IVF clinical practice. WIDER IMPLICATIONS OF THE FINDINGS: FV and FW protocols offer a promising alternative to conventional methods, enhancing laboratory workflow efficiency and reducing oocyte exposure to potentially harmful cryoprotectants. These findings lay the foundation for translational research and future clinical applications in clinical IVF settings. STUDY FUNDING/COMPETING INTEREST(S): This study was privately funded by Conceivable Life Sciences and Embryotools S.L. N.C.-B. reports stock with Embryotools and stock options with Conceivable Life Sciences and Fertility. N.C.-B. is also salaried by Embryotools. A.C.-B. received support for attending meetings from Conceivable Life Sciences and holds patents and stock with Conceivable Life Sciences, and stock with Hope IVF Mexico and IVF 2.0. A.F.-S.F. has received travel support from Conceivable Life Sciences and has patents with them as well as stock options. A.C. is salaried by IVIRMA. J.C. is salaried by Conceivable Life Sciences, holds stock options with Conceivable Life Sciences, IVF 2.0 and Athea Science and has other financial/non-financial interests with Reproduction Healthcare and TMRW Life Science. TRIAL REGISTRATION NUMBER: NA.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Costa-Borges N, Matia-Algué Q, Coello A, et al. Preclinical validation of fast oocyte vitrification and warming protocols with comparable efficiencies to a standard method. Hum Reprod. 2025. PMID: 40334080. doi:10.1093/humrep/deaf069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。